PRELIMINARY TRIAL OF SPECIFIC TARGETING THERAPY AGAINST MALIGNANT GLIOMA

被引:238
作者
NITTA, T
SATO, K
YAGITA, H
OKUMURA, K
ISHII, S
机构
[1] JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,2-1-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN
[2] JUNTENDO UNIV,SCH MED,DEPT NEUROL SURG,TOKYO 113,JAPAN
关键词
D O I
10.1016/0140-6736(90)90205-J
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The results of specific targeting therapy by use of lymphokine-activated killer (LAK) cells treated with bispecific antibody in 10 patients with malignant glioma were compared with the results of therapy with untreated LAK cells in 10 other patients. Both treated and untreated cells were given locally. The bispecific antibody was an anti-CD3 monoclonal antibody (mAb) chemically conjugated to anti-glioma mAb. Of the 10 patients given specific targeting therapy, 4 showed regression of tumour, and in another 4 patients computed tomography and histology suggested eradication of the glioma cells left behind after surgery. No recurrence was detected in the 10 to 18 months of follow-up. Patients receiving untreated LAK cells had recurrences within 1 year except in 1 case, and 8 patients died within 4 years. So far specific targeting therapy seems to be a new useful form of adoptive immunotherapy. © 1990.
引用
收藏
页码:368 / 371
页数:4
相关论文
共 24 条
  • [1] BURGER PC, 1987, CANCER, V59, P1617, DOI 10.1002/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO
  • [2] 2-X
  • [3] INCREASED VASCULAR-PERMEABILITY IN ORGANS MEDIATED BY THE SYSTEMIC ADMINISTRATION OF LYMPHOKINE-ACTIVATED KILLER CELLS AND RECOMBINANT INTERLEUKIN-2 IN MICE
    ETTINGHAUSEN, SE
    PURI, RK
    ROSENBERG, SA
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (03): : 177 - 188
  • [4] LYMPHOKINE-ACTIVATED KILLER CELL PHENOMENON - LYSIS OF NATURAL KILLER-RESISTANT FRESH SOLID TUMOR-CELLS BY INTERLEUKIN 2-ACTIVATED AUTOLOGOUS HUMAN PERIPHERAL-BLOOD LYMPHOCYTES
    GRIMM, EA
    MAZUMDER, A
    ZHANG, HZ
    ROSENBERG, SA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (06) : 1823 - 1841
  • [5] LYMPHOKINE-ACTIVATED KILLER CELL PHENOMENON .2. PRECURSOR PHENOTYPE IS SEROLOGICALLY DISTINCT FROM PERIPHERAL LYMPHOCYTES-T, MEMORY CYTO-TOXIC THYMUS-DERIVED LYMPHOCYTES, AND NATURAL-KILLER CELLS
    GRIMM, EA
    RAMSEY, KM
    MAZUMDER, A
    WILSON, DJ
    DJEU, JY
    ROSENBERG, SA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1983, 157 (03) : 884 - 897
  • [6] AUTOLOGOUS TUMOR-SPECIFIC CYTO-TOXIC LYMPHOCYTES-T IN THE INFILTRATE OF HUMAN METASTATIC MELANOMAS - ACTIVATION BY INTERLEUKIN-2 AND AUTOLOGOUS TUMOR-CELLS, AND INVOLVEMENT OF THE T-CELL RECEPTOR
    ITOH, K
    PLATSOUCAS, CD
    BALCH, CM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (04) : 1419 - 1441
  • [7] JACOBS SK, 1986, CANCER RES, V46, P2101
  • [8] JOHNSON GD, 1978, HDB EXPT IMMUNOLOGY, V3, P1
  • [9] AN INVITRO MODEL FOR TUMOR-IMMUNOTHERAPY WITH ANTIBODY HETEROCONJUGATES
    JUNG, G
    EBERHARD, HJM
    [J]. IMMUNOLOGY TODAY, 1988, 9 (09): : 257 - 260
  • [10] LOTZE MT, 1986, CANCER, V58, P2764, DOI 10.1002/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO